botensilimab
AssetAlso BOT, Botvymo, AGEN-1181
Fc-enhanced anti-CTLA-4 antibody enhancing immune responses against tumours
- Stage
- Approved
- Modality
- Antibody
- Target
- Inflammation
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Microsatellite stable metastatic colorectal cancer
Approved, businesswire.com, 8 Oct 2026
Ovarian cancer
Phase 1, businesswire.com, 3 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Competitors4
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.